Articles Alert

LIFE SCIENCES BY BERNARD DIXON European Editorial Offices The Scientist Uxbridge, U.K. "Are the malignancies in AIDS patients secondary consequences of their immunodeficient state? Or are they caused by the virus itself? New evidence suggests that the principal type of tumor is induced by a single viral gene. But why, then, is that tumor almost unknown in hemophiliacs with AIDS? J. Vogel, S.H. Hinricha, R.K. Reynolds, P.A. Luciw, G. Jay, “The HIV tat gene induces dermal lesions resemb

Written byBernard Dixon
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

BY BERNARD DIXON
European Editorial Offices
The Scientist
Uxbridge, U.K.

"Are the malignancies in AIDS patients secondary consequences of their immunodeficient state? Or are they caused by the virus itself? New evidence suggests that the principal type of tumor is induced by a single viral gene. But why, then, is that tumor almost unknown in hemophiliacs with AIDS?

J. Vogel, S.H. Hinricha, R.K. Reynolds, P.A. Luciw, G. Jay, “The HIV tat gene induces dermal lesions resembling Kaposi’s sarcoma in transgenic mice,” Nature, 335 (6191), 606-11, 13 October 1988.

" Although the engineering of antibodies is barely four years old, progress has been astonishingly fast. This year’s arguably most spectacular breakthrough is the production of a catalytic antibody that can wrench amide bonds apart—presaging “abzymes” for cutting proteins at specific sites.

K.D. Janda, D. Schloeder, S.J. Benkovic, R.A. Lerner, “Induction of an antibody that catalyzes the hydrolysis of an amide ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies